Liver lesions shrank after treatment with octreotide and Lutetium-177 vipivotide tetraxetan...The role of microsatellite instability (MSI) as a screening marker, and personalized treatment approaches like immunotherapy for dMMR tumors. Understanding these correlations may assist in early discovery, surveillance, and customized treatment for patients dealing with LS-associated malignancies.

P4, N=20, Not yet recruiting, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

The aim of this work is to evaluate [89Zr]Zr-DFO-TATE and [89Zr]Zr-DFO-TOC for PET imaging of SSTR+ NETs. This study seeks to provide a comprehensive in vivo comparison of the two agents including the in vivo PET imaging, ex vivo biodistribution, and internal radiation dosimetry, with the overarching goal of advancing precision diagnostics and improving therapeutic planning for NET patients undergoing [177Lu]Lu-DOTA-TATE therapy.

P=N/A, N=1067, Not yet recruiting, Novartis Pharmaceuticals

The addition of everolimus, a mammalian target of rapamycin inhibitor, to octreotide marginally improves the 6-month progression-free survival (PFS) rate...We present the first case of a refractory meningioma patient treated with combination PRRT and octreotide in a 66-year-old male who received 177Lu-DOTATATE 7.4 GBq (200 mCi) and intramuscular long-acting octreotide 40 mg every 8 weeks for four cycles followed by a single cycle of octreotide 40 mg monotherapy...A 7-week post-treatment MRI brain demonstrated stable disease with 11.5% reduction per RANO-Meningioma and a 2.6% reduction per RECIST 1.1 criteria. Combined PRRT and octreotide represents a promising therapeutic strategy for patients with refractory meningioma.

P1, N=29, Not yet recruiting, NYU Langone Health

Radioimmunotherapy with anti-CD20 agents, including 90Y-ibritumomab tiuxetan and 131I-tositumomab, demonstrated meaningful efficacy in B-cell non-Hodgkin lymphoma, particularly in indolent and relapsed/refractory settings. Available evidence supports the plausibility and possible clinical utility of these approaches, but remains heterogeneous and, for several newer targets, preliminary. Future development will require prospective trials, standardized imaging-based selection, individualized dosimetry, and integration within multidisciplinary lymphoma treatment pathways.

P=N/A, N=64, Not yet recruiting, University of California, San Francisco | Trial completion date: Dec 2028 --> Mar 2029 | Initiation date: May 2026 --> Oct 2026 | Trial primary completion date: Dec 2028 --> Mar 2029

P=N/A, N=140, Not yet recruiting, Boston Scientific Corporation

P2, N=60, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Apr 2033 --> Jul 2033 | Initiation date: Apr 2026 --> Jul 2026 | Trial primary completion date: Apr 2032 --> Jul 2032

P1, N=22, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | N=48 --> 22

P1/2, N=20, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | N=58 --> 20